微球
Search documents
鼎龙股份(300054):拟收购皓飞新材切入锂电功能辅材新赛道
Xin Lang Cai Jing· 2026-02-04 10:35
Group 1 - The company expects to achieve a net profit attributable to shareholders of 700-730 million yuan in 2025, representing a year-on-year growth of approximately 34.44%-40.20%, driven by strong growth in semiconductor and display materials business and effective cost control measures [1] - The company anticipates a non-deductible net profit attributable to shareholders of 661-691 million yuan in 2025, with a year-on-year increase of about 41.00%-47.40%, while non-recurring gains and losses are estimated at 39 million yuan for the current reporting period [1] Group 2 - The company plans to acquire 70% equity of Haofei New Materials for 630 million yuan, marking its entry into the lithium battery functional auxiliary materials sector, which is expected to benefit from the growing demand in the new energy vehicle and energy storage industries [2] - The domestic market size for lithium battery binders and dispersants is projected to exceed 20 billion yuan by 2030, with Haofei New Materials being a leading player in this segment, having established strong relationships with top clients in the power and energy storage battery sectors [2] - The company aims to leverage its existing materials business to enhance synergies with the lithium battery business, optimizing production and quality control through its mature management systems [2] Group 3 - Revenue projections for the company are estimated at 3.779 billion yuan, 4.648 billion yuan, and 5.611 billion yuan for the years 2025, 2026, and 2027 respectively, with net profits attributable to shareholders expected to be 720 million yuan, 950 million yuan, and 1.26 billion yuan for the same years [3]
纳微科技:公司目前还没有您提及领域的微球应用收入
Ge Long Hui· 2026-02-03 10:25
格隆汇2月3日丨纳微科技(688690.SH)在投资者互动平台表示,公司目前还没有您提及领域的微球应用 收入。 ...
鼎龙股份:拟收购皓飞新材切入锂电功能辅材新赛道-20260203
China Post Securities· 2026-02-03 10:24
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [5][13]. Core Insights - The company is projected to achieve a net profit attributable to shareholders of 7-7.3 billion yuan in 2025, representing a year-on-year growth of approximately 34.44%-40.20% [3]. - The acquisition of 70% equity in Haofei New Materials for 630 million yuan marks the company's entry into the lithium battery functional materials sector, which is expected to benefit from the growing demand in the new energy vehicle and energy storage markets [4]. - The company anticipates a non-recurring profit of approximately 39 million yuan for the reporting period, compared to 51.89 million yuan in the same period last year, primarily from government subsidies [3]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are 37.79 billion yuan, 46.48 billion yuan, and 56.11 billion yuan, respectively, with net profits of 7.2 billion yuan, 9.5 billion yuan, and 12.6 billion yuan [5][9]. - The company expects a significant increase in its net profit margin, with net profit margins projected to be 19.0% in 2025 and 22.5% in 2027 [12]. - The earnings per share (EPS) is forecasted to grow from 0.76 yuan in 2025 to 1.33 yuan in 2027, reflecting a strong upward trend in profitability [9][12].
鼎龙股份(300054):拟收购皓飞新材切入锂电功能辅材新赛道
China Post Securities· 2026-02-03 07:52
Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [5][13]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of 7-7.3 billion yuan in 2025, representing a year-on-year growth of approximately 34.44%-40.20% [3]. - The acquisition of 70% equity in Haofei New Materials for 630 million yuan marks the company's entry into the lithium battery functional materials sector, which is projected to see significant growth due to demand from the new energy vehicle and energy storage industries [4]. - The company anticipates revenue of 37.79 billion yuan in 2025, with net profits of 7.2 billion yuan, and expects continued growth in subsequent years [5]. Company Overview - The latest closing price of the company's stock is 42.25 yuan, with a total market capitalization of 40 billion yuan [2]. - The company has a total share capital of 9.47 billion shares, with 7.37 billion shares in circulation [2]. - The company's first major shareholder is Zhu Shuangquan [2]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are 37.79 billion yuan, 46.48 billion yuan, and 56.11 billion yuan, respectively [5]. - The expected net profit attributable to shareholders for the same years is 7.2 billion yuan, 9.5 billion yuan, and 12.6 billion yuan [5]. - The company’s EBITDA is projected to grow from 1.37 billion yuan in 2025 to 2.18 billion yuan in 2027 [9]. Market Position - The lithium battery materials market is expected to exceed 20 billion yuan by 2030, with Haofei New Materials positioned as a leading player in this segment [4]. - The company plans to leverage its existing materials business to enhance synergies with the new lithium battery operations, optimizing production and quality control [4].
公司问答丨赛分科技:公司目前已具备自产微球的能力
Ge Long Hui A P P· 2026-01-28 08:39
赛分科技回复称,公司目前已具备自产微球的能力。公司掌握了不同基质(琼脂糖、聚合物、硅胶)微球 材料制备的技术,对微球粒径、孔径、机械强度等能够进行精确调控。公司可合成粒径在1.7~125μm 微球,粒径分布精准控制1.1-1.3之间,孔径覆盖6nm-400nm等不同规格。此外,公司针对不同应用领域 开发合成出不同机械强度的微球,提高了产品选择性,可满足色谱填料的生产需求。 格隆汇1月28日|有投资者在互动平台向赛分科技提问:请问贵司在纯化工艺过程中所使用的微球材料 是公司自给自足的还是向外采购的? ...
赛分科技(688758.SH):目前已具备自产微球的能力
Ge Long Hui· 2026-01-28 07:48
格隆汇1月28日丨赛分科技(688758.SH)在互动平台表示,公司目前已具备自产微球的能力。公司掌握了 不同基质(琼脂糖、聚合物、硅胶)微球材料制备的技术,对微球粒径、孔径、机械强度等能够进行精 确调控。公司可合成粒径在1.7~125μm微球,粒径分布精准控制1.1-1.3之间,孔径覆盖6nm-400nm等不 同规格。此外,公司针对不同应用领域开发合成出不同机械强度的微球,提高了产品选择性,可满足色 谱填料的生产需求。 ...
纳微科技:公司关注微球在药物制剂领域的应用机会 有计划采取与药企合作研发方式推进项目转化
Zheng Quan Ri Bao Wang· 2025-12-18 09:43
Group 1 - The company focuses on the core business of biopharmaceutical separation and purification while exploring opportunities for microspheres in drug formulation [1] - The company plans to collaborate with pharmaceutical companies for research and development to advance project conversion [1] - The drug application project conversion cycle is long and will not contribute to the company's current operating performance [1]